| Expression pattern: |
DN |
| Associated gene: |
HBx, RBM15, YTHDF2, HRSP12, POP1, YBX1, MET, AKT, PDK-1 |
| Associated microRNA: |
- |
| Biological function: |
inhibits proliferation, stemness, and tumorigenicity of HCC cells |
| Molecular mechanism: |
HBx promotes RBM15-driven m6A modification of cFAM210A and its YTHDF2-HRSP12-RNase P/MRP-mediated degradation; cFAM210A binds YBX1 and inhibits YBX1 Ser102 phosphorylation, reducing YBX1 transactivation of MET |
| Biological pathway or process: |
proliferation (inhibits); stemness (inhibits); m6A modification (other); ceRNA regulation (inhibits) |
| Detected method: |
Q
S
|
| Validation methods: |
circRNA-seq; RT-qPCR; divergent primers PCR; RNase R Treatment; Sanger Sequencing; Clinical Sample Validation; Actinomycin D / DRB Stability Assay; MeRIP / MeRIP-seq; Luciferase Reporter Assay; RNA Pull-Down; RIP (RNA Immunoprecipitation); FISH / smFISH; IF (Immunofluorescence); Western Blot; Transfection; CCK8; EdU Staining; Colony Formation Assay; In Vivo Animal Model; Survival Analysis |
| Clinical significance: |
Low cFAM210A expression is associated with poorer late recurrence-free survival in HBV-related HCC |
| Description: |
In HBV-related HCC, cFAM210A is down-regulated and acts as a tumor suppressor by inhibiting HCC cell proliferation, stemness and tumorigenicity. HBx induces RBM15-mediated m6A modification of cFAM210A and promotes its YTHDF2-HRSP12-RNase P/MRP-dependent degradation. cFAM210A binds YBX1, inhibits YBX1 Ser102 phosphorylation, and suppresses YBX1 transactivation of MET, linking low cFAM210A to worse recurrence outcomes. |
| Confidence score: |
0.8712 |